MXPA02009434A - Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion. - Google Patents

Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.

Info

Publication number
MXPA02009434A
MXPA02009434A MXPA02009434A MXPA02009434A MXPA02009434A MX PA02009434 A MXPA02009434 A MX PA02009434A MX PA02009434 A MXPA02009434 A MX PA02009434A MX PA02009434 A MXPA02009434 A MX PA02009434A MX PA02009434 A MXPA02009434 A MX PA02009434A
Authority
MX
Mexico
Prior art keywords
diseases
leucopoiesis
acarinosis
tumour
stimulation
Prior art date
Application number
MXPA02009434A
Other languages
English (en)
Inventor
Hansjouml Eibl
Original Assignee
Haften E V Max Planck Ges Zur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haften E V Max Planck Ges Zur filed Critical Haften E V Max Planck Ges Zur
Publication of MXPA02009434A publication Critical patent/MXPA02009434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MXPA02009434A 2000-03-30 2001-03-29 Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion. MXPA02009434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10015814A DE10015814A1 (de) 2000-03-30 2000-03-30 Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
PCT/EP2001/003609 WO2001072289A2 (de) 2000-03-30 2001-03-29 Arzneimittel zur stimulierung der leukopoese, zur behandlung von tumor- und protozoenerkrankungen, von akarinosis, arthropodiasis und verfahren zu seiner herstellung

Publications (1)

Publication Number Publication Date
MXPA02009434A true MXPA02009434A (es) 2003-09-22

Family

ID=7636966

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009434A MXPA02009434A (es) 2000-03-30 2001-03-29 Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.

Country Status (11)

Country Link
US (1) US20030199476A1 (es)
EP (1) EP1267943A2 (es)
JP (1) JP2003528134A (es)
CN (1) CN1426311A (es)
AU (1) AU2001263828A1 (es)
BR (1) BR0109799A (es)
CA (1) CA2404322A1 (es)
DE (1) DE10015814A1 (es)
IL (1) IL151926A0 (es)
MX (1) MXPA02009434A (es)
WO (1) WO2001072289A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10148066A1 (de) * 2001-09-28 2003-04-24 Max Planck Gesellschaft Liposome enthaltend (Ether)-Lysolecithine
DE10148067A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
ES2184650B1 (es) * 2001-10-10 2004-09-16 Farmaleis, S.L. Utilizacion de colesterol y fosfolipidos en medicamentos para el tratamiento de la leishmaniasis en los canidos.
BRPI0516937A (pt) * 2004-10-19 2008-09-23 Max Planck Gesellschaft formulações com alquilfosfocolinas na utilização de partìculas portadoras de carga negativa
EP1745788A1 (de) 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
MX2015001963A (es) * 2012-08-13 2015-06-04 Adipharm Ead Formulaciones farmaceuticas que contienen derivados con 3-(4-cinamil-1-piperazinil)-amino de 3-formilrifamicinas sv y 3-formilrifamicina s y un proceso para su preparacion.
EP3895709A1 (de) 2020-04-17 2021-10-20 Andreas Hettich GmbH & Co. KG Phospholipide und phospholipid-metaboliten zur behandlung von viralen und bakteriellen lungenentzündungen und sepsis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI874742A (fi) * 1987-10-28 1989-04-29 K & V Licencing Oy Foerfarande foer framstaellning av liposomer.
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
ATE244254T1 (de) * 1996-02-16 2003-07-15 Max Planck Gesellschaft Phosphatidyloligoglycerine
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten

Also Published As

Publication number Publication date
WO2001072289A3 (de) 2002-04-18
DE10015814A1 (de) 2001-10-11
IL151926A0 (en) 2003-04-10
US20030199476A1 (en) 2003-10-23
WO2001072289A2 (de) 2001-10-04
BR0109799A (pt) 2003-01-21
CA2404322A1 (en) 2002-09-24
AU2001263828A1 (en) 2001-10-08
EP1267943A2 (de) 2003-01-02
JP2003528134A (ja) 2003-09-24
CN1426311A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
EP1455778A4 (en) METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
EP1374935A4 (en) MEDICAL SYRINGE AND METHOD FOR THE PRODUCTION THEREOF
HK1079993A1 (en) Drugs for treating vascular diseases
HU0200493D0 (en) Method for the treatment of nuclear factor-kappa b mediated diseases and disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002349630A1 (en) Medical treatment system and production method therefor
AU2002357830A1 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
HUP0402656A3 (en) A cell therapy method for the treatment of tumors
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
SG116507A1 (en) Pharmaceutical dosage form and method of making.
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.
AU2003292880A1 (en) A drop pill of treating and preventing from cardio-cerebral diseases and the process of producing thereof
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU7345400A (en) A method of treatment of human immunodeficiency diseases
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
AU2000229021A1 (en) A medicine for treating obesity and the method of producing thereof
AU2003211258A1 (en) Stent for intracranial vascular therapy and process for producing the same
AU2001258575A1 (en) Treatment of cancer and neurological diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal